Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast(R) to Maintain Glycemic Control in Patients with Type 2 Diabetes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today the publication of clinical data highlighting the ability of Glufast® (mitiglinide calcium hydrate) monotherapy, or combination therapy with metformin, to manage glucose surges before and after meals. The data were published in the Abstract Book for the American Diabetes Association 67th Annual Scientific Sessions in Chicago, Illinois. Glufast is an insulin secretagogue that lowers postprandial (post-meal) glucose levels by improving the body's own ability to produce insulin. Marketed in Japan since 2004, Glufast has an extensive clinical package that demonstrates the product's ability to effectively and safely treat Type 2 diabetes.

Back to news